Sociedad Americana de Hirudoterapia

Association between thrombophilic gene variants and thrombosis in the Iranian population: a systematic review and meta-analysis

Systematic review published in Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Meta-analysisEnsayos clínicosSafdari SM et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2025

Abstract

Thrombophilia is influenced by genetic variants, such as Factor V Leiden (FVL) and the prothrombin G20210A mutation. In clinical settings, assessing numerous genetic factors can lead to diagnostic errors and unnecessary treatments. This meta-analysis examines gene variants associated with thrombosis in the Iranian population, where their role in thrombotic disorders remains underexplored. A systematic literature search was performed across PubMed, Scopus, and Web of Science, targeting case-control studies published up to July 2025. Studies were included if they evaluated thrombophilia-related polymorphisms in Iranian patients with various thrombotic conditions, such as recurrent pregnancy loss (RPL), venous thromboembolism (VTE), or deep vein thrombosis (DVT). Advanced statistical analyses, including random-effects models, fixed-effects models, and Bayesian meta-analysis, were used to compute odds ratios (ORs) and 95% confidence intervals (CIs). From 36 studies encompassing over 14 000 participants, significant associations emerged. For RPL, FVL G1691A heterozygote (OR: 1.998, 95% CI: 1.02-3.88), methylenetetrahydrofolate reductase (MTHFR) C677T heterozygote (OR: 1.77, 95% CI: 1.31-2.39), MTHFR A1298C heterozygote (OR: 3.10, 95% CI: 1.33-7.20) and homozygote (OR: 1.69, 95% CI: 1.05-2.70), prothrombin G20210A heterozygote (OR: 2.435, 95% CI: 1.09-5.39) and homozygote (OR: 0.487, 95% CI: 0.40-0.58), plasminogen activator inhibitor-1 (PAI-1) polymorphisms, factor V (FV) A4070G, FV 5279A/G, factor XIII (FXIII) Val34Leu, and integrin subunit beta-3 (ITGB3)1565T/C were linked to elevated RPL risk. Additionally, FVL G1691A heterozygote (OR: 5.25, 95% CI: 2.39-11.54) was associated with higher VTE risk, while MTHFR C677T heterozygote (OR: 1.404, 95% CI: 1.030-1.914) increased DVT risk. These ethnicity-specific findings highlight critical genetic risk factors for thrombotic disorders in Iranians, potentially guiding precise diagnostics and personalized interventions.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleSystematic ReviewMeta-Analysis
Indexed MeSH termsHumansIranThrombophiliaFactor VThrombosisFemaleProthrombinMethylenetetrahydrofolate Reductase (NADPH2)Genetic Predisposition to DiseasePregnancy

Resumen

Thrombophilia is influenced by genetic variants, such as Factor V Leiden (FVL) and the prothrombin G20210A mutation. In clinical settings, assessing numerous genetic factors can lead to diagnostic errors and unnecessary treatments.

Por qué esto importa para la hirudoterapia

Esta revisión sistemática y metaanálisis de 36 estudios de casos y controles (más de 14,000 participantes) cuantificó cómo las variantes genéticas trombofílicas, Factor V Leiden, protrombina G20210A, MTHFR, PAI-1 y otras, se asocian con la pérdida recurrente del embarazo, la tromboembolia venosa y la trombosis venosa profunda en la población iraní, reportando razones de momios elevadas para varias variantes. Para la ASH, constituye un antecedente sobre quién porta el riesgo de hipercoagulabilidad heredado, el contexto del paciente en el cual se considera cualquier estrategia antitrombótica (farmacológica o el secretoma anticoagulante natural de la sanguijuela). Advertencia honesta: esta es evidencia de epidemiología genética que resume otros estudios en una población étnica, con alta relevancia para la estratificación del riesgo de trombosis pero ninguna para el tratamiento; no dice nada sobre la hirudoterapia, las sanguijuelas ni ninguna intervención terapéutica.

Citación

Association between thrombophilic gene variants and thrombosis in the Iranian population: a systematic review and meta-analysis.

Safdari SM et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.